Brian Allen Carrico Acquires 8,060 Shares of NeurAxis (NASDAQ:NRXS) Stock

NeurAxis, Inc. (NASDAQ:NRXS) CEO Brian Allen Carrico bought 8,060 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was purchased at an average price of $1.96 per share, for a total transaction of $15,797.60. Following the completion of the acquisition, the chief executive officer owned 348,178 shares in the company, valued at $682,428.88. This represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

NeurAxis Price Performance

NASDAQ:NRXS opened at $7.25 on Friday. NeurAxis, Inc. has a one year low of $1.33 and a one year high of $7.97. The company has a market cap of $81.11 million, a PE ratio of -3.94 and a beta of 2.49. The firm has a 50-day moving average of $5.80 and a 200-day moving average of $4.16.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. bought a new stake in NeurAxis during the 4th quarter worth approximately $1,299,000. Money Concepts Capital Corp raised its position in shares of NeurAxis by 566.6% in the fourth quarter. Money Concepts Capital Corp now owns 222,605 shares of the company’s stock worth $1,011,000 after buying an additional 189,210 shares in the last quarter. Geode Capital Management LLC boosted its stake in NeurAxis by 48.8% during the fourth quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock valued at $343,000 after buying an additional 24,817 shares during the period. Manatuck Hill Partners LLC purchased a new stake in shares of NeurAxis in the 2nd quarter valued at about $122,000. Finally, Citadel Advisors LLC boosted its position in shares of NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after acquiring an additional 10,103 shares during the last quarter. Institutional investors own 11.77% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum upped their price objective on shares of NeurAxis from $8.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $13.00.

About NeurAxis

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.